Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.78 |
| ▸ | CASP3 | P42574 | 1/20 | 0.78 |
| ▸ | CASP6 | P55212 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.72 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | MC4R | P32245 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899656 | 1.00 | ADRB2 (0.78) | ADRB2CASP3CASP6MAPK1CYP3A4 | |
| SCHEMBL7154320 | 0.92 | ADRB2 (0.68) | ADRB2CASP3CASP6MAPK1CYP3A4 | |
| SCHEMBL7154315 | 0.92 | ADRB2 (0.68) | ADRB2CASP3CASP6MAPK1CYP3A4 | |
| SCHEMBL8986831 | 0.89 | ADRB2 (0.68) | ADRB2CASP3CASP6MAPK1CYP3A4 | |
| SCHEMBL11807907 | 0.89 | ADRB2 (0.74) | ADRB2CASP3CASP6MAPK1CYP3A4 | |
| SCHEMBL7149088 | 0.89 | ADRB2 (0.74) | ADRB2CASP3CASP6MAPK1CYP3A4 | |
| SCHEMBL7149089 | 0.89 | ADRB2 (0.74) | ADRB2CASP3CASP6MAPK1CYP3A4 | |
| SCHEMBL11810215 | 0.87 | ADRB2 (0.73) | ADRB2CASP3CASP6MAPK1CYP3A4 | |
| SCHEMBL8850480 | 0.86 | ADRB2 (0.80) | ADRB2CASP3CASP6MAPK1CYP3A4 | |
| SCHEMBL18326512 | 0.86 | ADRB2 (0.77) | ADRB2CASP3CASP6MAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-25 | — | — | US | disclosed |
| US-10617654-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-04-14 | — | — | US | disclosed |
| US-10562843-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2019-08-15 | — | — | US | disclosed |
| US-10308591-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190076379-A1 | METHODS OF TREATING BREAST CANCER | MITCHELL WOODS PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190008802-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | The USA, as represented by the Secretary, Departme nt of Health and Human Services (US) | 2019-01-10 | — | — | US | disclosed |
| US-10130594-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-20 | — | — | US | disclosed |
| EP-2544676-B1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | US HEALTH (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-2544676-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | SRI INTERNATIONAL | 2013-01-03 | — | — | US | disclosed |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | Services, National Institutes of Health | 2012-06-21 | — | — | US | disclosed |
| WO-2011112867-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-07-01 | — | — | US | disclosed |
| EP-2064174-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008022038-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1660035-A2 | LIQUID COMPOSITIONS COMPRISING FORMOTEROL | Dey L.P. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005007142-A2 | LIQUID COMPOSITIONS COMPRISING FORMOTEROL | DEY L.P. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-0658538-B1 | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA INC (US) | 1997-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617654-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885CASP3 4325/4885CASP6 4720/4885 |
| US-20190076379-A1 | METHODS OF TREATING BREAST CANCER | CNR2, ADRB2, CNR1 | ADRB2 2/4885CASP3 2427/4885CASP6 3402/4885 |
| US-10562843-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885CASP3 4436/4885CASP6 4847/4885 |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885CASP3 4187/4885CASP6 4642/4885 |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885CASP3 4436/4885CASP6 4847/4885 |
| US-10308591-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885CASP3 4578/4885CASP6 4855/4885 |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885CASP3 4436/4885CASP6 4847/4885 |
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885CASP3 4325/4885CASP6 4720/4885 |
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885CASP3 4436/4885CASP6 4847/4885 |
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885CASP3 4325/4885CASP6 4720/4885 |
| US-20190008802-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885CASP3 4325/4885CASP6 4720/4885 |
| US-10130594-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885CASP3 4362/4885CASP6 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.